CARIS LIFE SCIENCES, INC.

Role of molecular profiling in cancer care; access to molecular profiling technologies in Medicare; prior authorization reform in Medicare; Date of Service Rule Reform for lab services; Medicare payment for Software as a Medical Service (SaMS); appropriate reimbursement for cutting edge cancer diagnostic testing, including PAMA reporting; role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools; S 2355, Patients Deserve Price Tags;

Role of molecular profiling in cancer care; access to molecular profiling technologies in Medicare; prior authorization reform in Medicare; Date of Service Rule Reform for lab services; Medicare payment for Software as a Medical Service (SaMS); appropriate reimbursement for cutting edge cancer diagnostic testing, including PAMA reporting; role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools; S 2355, Patients Deserve Price Tags;

Role of molecular profiling in cancer care; access to molecular profiling technologies in Medicare; prior authorization reform in Medicare; Date of Service Rule Reform for lab services; Medicare payment for Software as a Medical Service (SaMS); appropriate reimbursement for cutting edge cancer diagnostic testing, including PAMA reporting; role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools; S 2355, Patients Deserve Price Tags;